ALLO

Allogene Therapeutics, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

ALLOAllogene Therapeutics
0Calm
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Signing up patientsPhase 2250 patientsMain results: Dec 2027
ALLOAllogene Therapeutics
0Calm
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Running, no new patientsPhase 1/2160 patientsMain results: Feb 2029

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

2 sales (2 not pre-planned) · 0 purchases

Parker Geoffrey M.CHIEF FINANCIAL OFFICER · Oct 21, 2026Sold 36,342 sharesabout $49 thousand · not pre-planned
Douglas Earl MartinSVP, General Counsel · Aug 21, 2026Sold 29,697 sharesabout $63 thousand · not pre-planned

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.